NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Endometrial Basis for Infertility in Women with Recurrent Implantation Failure and Pregnancy Loss

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Child Health and Human Development (NICHD)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Female
Min Age: 18
Max Age: 42

Referral Letter Required


Population Exclusion(s)



Natural History

Recruitment Keyword(s)



Normal Endometrial Physiology

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Institute of Child Health and Human Development


Pregnancy loss is the most common complication of pregnancy. It occurs in roughly one-half

of natural conceptions. It most frequently occurs in the first 2 to 3 weeks of pregnancy. Researchers want to look at the lining of the uterus, called the endometrium, to see what role it plays in implantation and miscarriage.


To gain a better understanding of how normal and abnormal endometrium works.


Healthy, fertile women ages 18-42 who have had one prior child.


Participants will have 3 study visits.

At visit 1, participants will have a medical history. They will have a radiologic/imaging review if needed. They will be taught how to monitor their urine luteinizing hormone (LH) at home with an ovulation predictor kit. They will have their second study visit 9 days after their LH surge.

At visit 2, participants will take a urine pregnancy test. They will have a physical exam and have blood drawn. They will have a uterine lavage and endometrial biopsy. For this, a speculum will be placed into the vagina. A soft catheter will be inserted through the cervical canal into the uterus. Saline will be added into the uterus and then recovered after 30 seconds. A tissue sample will be taken.

About 46 days later, participants will start another round of LH monitoring. They will have a third study visit 9 days after their LH surge. At visit 3, they will repeat the tests from visit 2.

Some samples will be used for genetic tests.

Participation will last for 3 menstrual cycles.

--Back to Top--



In order to be eligible to participate in this study, an individual must meet all of the following criteria:

-Stated willingness to comply with all study procedures and availability for the duration of the study

-Female, aged 18-42, childbearing potential

-In good general health as evidenced by medical history, previous fertility or diagnosed with infertility with and without a previous pregnancy loss.

--Normal Fertile - Control- Women with proven parity based on spontaneous conception without fertility treatment or prior diagnosis of infertility, normal uncomplicated pregnancy, and birth of at least one healthy baby

--ART Infertile - Control-Women that are part of a couple diagnosed with unexplained infertility that conceived on the first embryo transfer (ET) attempt and meet inclusion/exclusion criteria.

--Early Implantation Failure (EIF) - Infertility defined by a failure to conceive after:

a) three or more failed transfers of high-quality blastocyst(s) (grade 3BB or higher); or b) two or more transfers of euploid blastocyst(s) (tested through trophectoderm biopsy and preimplantation genetic testing for aneuploidy (PGT- A) using next generation sequencing). These women will have a negative serum beta human chorionic gonadotropin (hCG) 12 days after ET.

--Early Pregnancy Failure (EPF) - Infertility defined by two or more biochemical pregnancies after transfer of a high-quality or euploid blastocyst with a positive hCG 12 days after ET but without subsequent clinical signs of pregnancy (detection of intrauterine or extrauterine gestational sac at 5-7 weeks of gestation). While, by definition these are pregnancies of unknown location (PUL) and will

include spontaneously resolving ectopic pregnancies, the vast majority of these will be failed intrauterine pregnancies.

--Recurrent Pregnancy Loss (RPL): Infertility defined by the loss of two or more pregnancies after transfer of a high-quality or euploid blastocyst with a positive HCG 12 days after ET and subsequent clinical signs of pregnancy (detection of an intrauterine gestational sac at 5-7 weeks gestation by ultrasound).

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

-Women with prior hysterectomy as they do not have an endometrium

-Postmenopausal women

-Women with a history of preterm delivery (<37-week gestation), preeclampsia and/or stillbirth are excluded.

-Women with RPL must screen negative for the antiphospholipid syndrome (negative lupus anticoagulant, negative IgG and IgM antiphospholipid antibodies and negative IgG and IgM anti-2GP1 antibodies)

-Women suffering from infertility with and without early pregnancy loss with prior diagnosis of common known disease risk factors, including disorders such as uterine anomalies, coagulopathy, balanced translocation, gynecological disease, other reproductive disorders and/or autoimmune conditions, pathology confirmed or suspected endometriosis, pathology confirmed or suspected adenomyosis, endometrial polyp(s) or submucosal fibroids, pathology confirmed acute or chronic endometritis, hydrosalpinx communicating with the endometrial cavity, history of Asherman syndrome, poorly controlled endocrinopathies, HIV infection, ovarian insufficiency and irregular menstrual cycles

-Women who are currently Pregnant as we would not be able to obtain an endometrial sample

-History of gonadotoxic therapy, precancerous (endometrial hyperplasia) or cancerous condition of the female reproductive tract,

-Current smoker or tobacco use or tobacco use within 30 days.

-Current use of reproductive hormones and/or fertility medications

-Current use of steroids or non-steroidal anti-inflammatory agents within the last 3 days.

-Women who are obese (BMI >30)

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Alan H. DeCherney, M.D.
National Institute of Child Health and Human Development (NICHD)
(301) 594-5494

Jasmine M. Aly, M.D.
National Institute of Child Health and Human Development (NICHD)
NIHBC 10 - CRC BG RM 5-5570
(718) 878-4717

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--